세계의 하지정맥류 치료 시장 규모, 점유율, 동향, 예측 : 제품, 시술, 최종사용자, 지역별(2025-2033년)

The global varicose vein treatment market size was valued at USD 458.8 Million in 2024. Looking forward, IMARC Group estimates the market to reach USD 696.9 Million by 2033, exhibiting a CAGR of 4.52% from 2025-2033. North America currently dominates the market, holding a market share of over 47.8% in 2024. The growing elderly population, technological advancements in minimally invasive (MI) procedures, increasing awareness and healthcare spending, and key players focusing on innovation and strategic collaborations to expand treatment options and geographic reach are some of the factors impelling the market growth.

Varicose Vein Treatment Market Analysis:

Major Market Drivers: The market is experiencing moderate growth because of the rising prevalence of varicose veins among the aging population and advancements in treatment technologies.

Key Market Trends: There is a shift towards less invasive treatment methods because of their efficacy, reduced pain, and shorter recovery periods compared to traditional surgical methods. Besides this, the growing integration of imaging technologies in varicose vein treatments, which enhances the precision of treatments and outcomes, is contributing to the growth of the market.

Geographical Trends: North America dominates the market, driven by high healthcare expenditure, advanced medical infrastructure, and increasing awareness about varicose vein conditions among the masses.

Competitive Landscape: Some of the major market players in the varicose vein treatment industry include Alma Lasers Ltd. (Sisram Medical Ltd.), Angiodynamics Inc., Biolitec AG (BioMed Technology Holdings Ltd.), Boston Scientific Corporation, Eufoton S.R.L., Fotona, Medtronic plc, Sciton Inc., Teleflex Incorporated, The Vein Company, VVT Medical Ltd. and WON TECH Co. Ltd., among many others.

Challenges and Opportunities: The growing cost of advanced varicose vein treatments, which can be prohibitive for patients without adequate insurance coverage, particularly in less developed regions, is influencing the market revenue. Nevertheless, this also creates a chance for industry participants to develop affordable solutions that can increase the availability of treatments to a wider range of people. Moreover, gaining more knowledge about health presents one of the major varicose vein treatment market recent developments to inform potential patients about the various treatment options, broadening the potential customer base.

Varicose Vein Treatment Market Trends:

Technological Advancements in Treatment

Ongoing advancements like endovenous laser therapy (EVLT), radiofrequency ablation (RFA), and ultrasound-guided sclerotherapy are changing treatment approaches from invasive surgeries to minimally invasive (MI) and non-surgical options. For patients, such new technologies promise quicker recovery, less pain, and smaller chances of post-operation complications, which is causing the popularity of the surgeries to grow. In 2023, the size of the global minimally invasive surgery market was US$ 52.9 Billion. As per the report by the IMARC Group, the market is expected to reach US$ 91.0 Billion by 2032, exhibiting a CAGR of 6% during 2024-2032. Further development of lasers and radiofrequency devices in combination with imaging technologies for more pinpoint treatment in the ailing veins is driving the varicose vein treatment demand. Companies are channelizing their revenues for research and development (R&D) to make the best use of technologies existing and to come up with new innovations.

Globalization of Healthcare

By partnering internationally, healthcare professionals exchange best practices and technologies, enhancing the quality of treatment globally. For instance, VVT Medical announced a strategic distribution agreement with Methapharm to market its ScleroSafe platform in the USA, following FDA approval in June 2023. This collaboration leverages Methapharm's expertise in varicose veins, aiming to transform treatment with ScleroSafe's innovative, non-thermal, non-tumescent technique. This worldwide exchange guarantees that advanced treatment techniques are available in different areas with standardization of care quality, supporting the varicose vein treatment market growth. Medical tourism is also a factor, with patients traveling overseas in search of top-notch treatments at more affordable prices. In 2023, the medical tourism industry in the world was valued at US$119.7 billion. The IMARC Group estimates the market would expand at a CAGR of 20.1% from 2024 to 2032, reaching US$ 650.8 billion in 2032. Globalization leads to increased accessibility and improved quality of varicose vein treatments worldwide, supporting market expansion and technological progress.

Regulatory Approvals and Support

Obtaining regulatory approvals and support is essential for advancing the development of varicose vein treatment. Regulatory agencies establish stringent criteria and provide clear approval procedures for new medical devices and treatments. The strict regulatory landscape motivates companies to invest in research and clinical trials to drive innovation. The approval of treatments by authorities builds trust and confidence between healthcare providers and patients, guaranteeing the presence of secure and efficient choices in the market. Furthermore, robust regulations can accelerate the entry of cutting-edge treatments into the market, quickening their adoption and expanding the range of modern options for varicose vein treatment. In April 2024, VVT Medical achieved a major milestone in the Korean market with the approval of its ScleroSafe(TM) device by the Korean Ministry of Food and Drug Safety. This was after the FDA 510(k) clearance and CE Mark, confirming ScleroSafe(TM) as a dependable option for varicose vein treatment.

Varicose Vein Treatment Market Segmentation:

Breakup by Product:

• Ablation Devices
• Radiofrequency Ablation Devices
• Laser Ablation Devices
• Others
• Sclerotherapy Injection
• Others

Ablation devices are an important segment, especially radiofrequency and laser ablation devices, because they are preferred in the treatment of varicose veins. These are effective in shutting off problematic veins with ways that are less invasive than those used hitherto, thereby inflicting less pain and delivering the patient to recovery quickly. Radiofrequency ablation devices utilize thermal energy to heat and collapse the vein, while laser ablation uses light energy to accomplish similar outcomes, providing effective options for patients who prefer less invasive treatments. In 2023, the market size of ablation devices worldwide reached US$ 5.9 billion. IMARC Group forecasts that the market will reach a value of US$ 14.4 billion by 2032, showing a 10.2% CAGR from 2024 to 2032.

Sclerotherapy injections have a solid presence in the industry, thereby influencing the varicose vein treatment market revenue. This technique includes injecting a solution into the varicose veins, which results in scarring and redirecting blood to healthier veins, ultimately causing the treated vein to vanish. The technique is used because of its effectiveness in addressing minor varicose veins and spider veins, its ease of use, and its reasonable cost. It is particularly popular in outpatient settings, where fast recovery is an important factor.

Others encompass a range of additional options, such as compression stockings and surgical procedures. Compression stockings are often utilized as a non-surgical method to control symptoms and delay the advancement of varicose veins, especially in the initial phases or mild instances. Surgical procedures, while less frequently used now because of the increase in minimally invasive (MI) techniques, are still utilized in serious situations when other treatments do not work. This part serves a wide range of patients, providing options from basic preventive care to extensive surgical treatments.

Breakup by Procedure:

• Injection Sclerotherapy
• Endovenous Ablation
• Surgical Ligation and Stripping

Injection sclerotherapy holds the largest share of the industry

Injection sclerotherapy is the most dominant sector in the varicose vein treatment industry, mainly because of its effectiveness, low level of invasiveness, and cost-effectiveness. The process includes injecting a sclerosant solution into the varicose veins to irritate the vein walls, leading them to collapse and bond. As time passes, the vein that has been treated fades away as it gets absorbed back into the surrounding tissue. The popularity of sclerotherapy is enhanced by its ability to be performed in outpatient settings, its quick resolution of cosmetic concerns and discomfort from small varicose and spider veins, and its short recovery time, making it a preferred option for patients wanting both effectiveness and convenience. In 2023, the sclerotherapy market in the world was valued at US$ 1.2 billion. The IMARC Group projects that the market will expand at a compound annual growth rate (CAGR) of 5.5% from 2024 to 2032, when it reaches US$ 2.0 billion in 2032.

Breakup by End User:

• Hospitals
• Clinics
• Ambulatory Centers

Hospitals represents the leading market segment

Hospitals dominate the market due to their extensive treatment options and ability to manage complicated cases that require advanced medical interventions, shaping a positive varicose vein treatment market outlook. They have the required infrastructure to offer various types of treatments for varicose veins, including less invasive procedures like sclerotherapy and endovenous ablation and more aggressive techniques such as surgical ligation and stripping. This section benefits a strong level of confidence from patients who are looking for dependable and efficient treatments from specialized vascular surgeons and interventional radiologists. Moreover, hospitals play a key role in are frequently the top choice for patients with advanced varicose veins who may need comprehensive care from various healthcare providers and extended monitoring, solidifying their position in the market.

Breakup by Region:

• North America
• United States
• Canada
• Asia-Pacific
• China
• Japan
• India
• South Korea
• Australia
• Indonesia
• Others
• Europe
• Germany
• France
• United Kingdom
• Italy
• Spain
• Russia
• Others
• Latin America
• Brazil
• Mexico
• Others
• Middle East and Africa

North America leads the market, accounting for the largest varicose vein treatment market share

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America represents the largest regional market for varicose vein treatment.

North America holds biggest share in the market, mainly due to substantial healthcare expenditure, cutting-edge medical technologies, and a solid healthcare system. This area, encompassing both the United States and Canada, shows a high need for minimally invasive (MI) procedures because of a high number of varicose veins in its elderly residents. As per the 2023 US Census Bureau report, the number of people in the US aged 65 and above was projected to increase by 47% from 58 million in 2022 to 82 million by 2050. Furthermore, it is expected that the percentage of people in this age range in the overall population will rise from 17% to 23%. Furthermore, North America is advantaged by having top healthcare firms and a strong regulatory framework that encourages quick uptake of new technologies. The strong presence of the region in the global market is also influenced by its extensive insurance coverage and high level of patient consciousness.

Competitive Landscape:

The market research report has also provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the major market players in the industry include Alma Lasers Ltd. (Sisram Medical Ltd.), Angiodynamics Inc., Biolitec AG (BioMed Technology Holdings Ltd.), Boston Scientific Corporation, Eufoton S.R.L., Fotona, Medtronic plc, Sciton Inc., Teleflex Incorporated, The Vein Company, VVT Medical Ltd. and WON TECH Co. Ltd.

Key Questions Answered in This Report

• 1.What is varicose vein treatment?
• 2.How big is the varicose vein treatment market?
• 3.What is the expected growth rate of the global varicose vein treatment market during 2025-2033?
• 4.What are the key factors driving the global varicose vein treatment market?
• 5.What is the leading segment of the global varicose vein treatment market based on procedure?
• 6.What is the leading segment of the global varicose vein treatment market based on end user?
• 7.What are the key regions in the global varicose vein treatment market?
• 8.Who are the key players/companies in the global varicose vein treatment market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Varicose Vein Treatment Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Product

• 6.1 Ablation Devices
  • 6.1.1 Market Trends
  • 6.1.2 Key Segments
    • 6.1.2.1 Radiofrequency Ablation Devices
    • 6.1.2.2 Laser Ablation Devices
    • 6.1.2.3 Others
  • 6.1.3 Market Forecast
• 6.2 Sclerotherapy Injection
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast
• 6.3 Others
  • 6.3.1 Market Trends
  • 6.3.2 Market Forecast

7 Market Breakup by Procedure

• 7.1 Injection Sclerotherapy
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Endovenous Ablation
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Surgical Ligation and Stripping
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast

8 Market Breakup by End User

• 8.1 Hospitals
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Clinics
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Ambulatory Centers
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast

9 Market Breakup by Region

• 9.1 North America
  • 9.1.1 United States
    • 9.1.1.1 Market Trends
    • 9.1.1.2 Market Forecast
  • 9.1.2 Canada
    • 9.1.2.1 Market Trends
    • 9.1.2.2 Market Forecast
• 9.2 Asia-Pacific
  • 9.2.1 China
    • 9.2.1.1 Market Trends
    • 9.2.1.2 Market Forecast
  • 9.2.2 Japan
    • 9.2.2.1 Market Trends
    • 9.2.2.2 Market Forecast
  • 9.2.3 India
    • 9.2.3.1 Market Trends
    • 9.2.3.2 Market Forecast
  • 9.2.4 South Korea
    • 9.2.4.1 Market Trends
    • 9.2.4.2 Market Forecast
  • 9.2.5 Australia
    • 9.2.5.1 Market Trends
    • 9.2.5.2 Market Forecast
  • 9.2.6 Indonesia
    • 9.2.6.1 Market Trends
    • 9.2.6.2 Market Forecast
  • 9.2.7 Others
    • 9.2.7.1 Market Trends
    • 9.2.7.2 Market Forecast
• 9.3 Europe
  • 9.3.1 Germany
    • 9.3.1.1 Market Trends
    • 9.3.1.2 Market Forecast
  • 9.3.2 France
    • 9.3.2.1 Market Trends
    • 9.3.2.2 Market Forecast
  • 9.3.3 United Kingdom
    • 9.3.3.1 Market Trends
    • 9.3.3.2 Market Forecast
  • 9.3.4 Italy
    • 9.3.4.1 Market Trends
    • 9.3.4.2 Market Forecast
  • 9.3.5 Spain
    • 9.3.5.1 Market Trends
    • 9.3.5.2 Market Forecast
  • 9.3.6 Russia
    • 9.3.6.1 Market Trends
    • 9.3.6.2 Market Forecast
  • 9.3.7 Others
    • 9.3.7.1 Market Trends
    • 9.3.7.2 Market Forecast
• 9.4 Latin America
  • 9.4.1 Brazil
    • 9.4.1.1 Market Trends
    • 9.4.1.2 Market Forecast
  • 9.4.2 Mexico
    • 9.4.2.1 Market Trends
    • 9.4.2.2 Market Forecast
  • 9.4.3 Others
    • 9.4.3.1 Market Trends
    • 9.4.3.2 Market Forecast
• 9.5 Middle East and Africa
  • 9.5.1 Market Trends
  • 9.5.2 Market Breakup by Country
  • 9.5.3 Market Forecast

10 SWOT Analysis

• 10.1 Overview
• 10.2 Strengths
• 10.3 Weaknesses
• 10.4 Opportunities
• 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

• 12.1 Overview
• 12.2 Bargaining Power of Buyers
• 12.3 Bargaining Power of Suppliers
• 12.4 Degree of Competition
• 12.5 Threat of New Entrants
• 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

• 14.1 Market Structure
• 14.2 Key Players
• 14.3 Profiles of Key Players
  • 14.3.1 Alma Lasers Ltd. (Sisram Medical Ltd.)
    • 14.3.1.1 Company Overview
    • 14.3.1.2 Product Portfolio
  • 14.3.2 Angiodynamics Inc.
    • 14.3.2.1 Company Overview
    • 14.3.2.2 Product Portfolio
    • 14.3.2.3 Financials
    • 14.3.2.4 SWOT Analysis
  • 14.3.3 Biolitec AG (BioMed Technology Holdings Ltd.)
    • 14.3.3.1 Company Overview
    • 14.3.3.2 Product Portfolio
  • 14.3.4 Boston Scientific Corporation
    • 14.3.4.1 Company Overview
    • 14.3.4.2 Product Portfolio
    • 14.3.4.3 Financials
    • 14.3.4.4 SWOT Analysis
  • 14.3.5 Eufoton S.R.L.
    • 14.3.5.1 Company Overview
    • 14.3.5.2 Product Portfolio
  • 14.3.6 Fotona
    • 14.3.6.1 Company Overview
    • 14.3.6.2 Product Portfolio
  • 14.3.7 Medtronic plc
    • 14.3.7.1 Company Overview
    • 14.3.7.2 Product Portfolio
    • 14.3.7.3 Financials
    • 14.3.7.4 SWOT Analysis
  • 14.3.8 Sciton Inc.
    • 14.3.8.1 Company Overview
    • 14.3.8.2 Product Portfolio
  • 14.3.9 Teleflex Incorporated
    • 14.3.9.1 Company Overview
    • 14.3.9.2 Product Portfolio
    • 14.3.9.3 Financials
    • 14.3.9.4 SWOT Analysis
  • 14.3.10 The Vein Company
    • 14.3.10.1 Company Overview
    • 14.3.10.2 Product Portfolio
  • 14.3.11 VVT Medical Ltd.
    • 14.3.11.1 Company Overview
    • 14.3.11.2 Product Portfolio
  • 14.3.12 WON TECH Co. Ltd
    • 14.3.12.1 Company Overview
    • 14.3.12.2 Product Portfolio
    • 14.3.12.3 Financials